Display options
Cite
Kowalczyk T, Kisluk J, Pietrowska K, et al. The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133314.
Kowalczyk, T., Kisluk, J., Pietrowska, K., Godzien, J., Kozlowski, M., Reszeć, J., Sierko, E., Naumnik, W., Mróz, R., Moniuszko, M., Kretowski, A., Niklinski, J., & Ciborowski, M. (2021). The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied. Cancers, 13(13), . https://doi.org/10.3390/cancers13133314
Kowalczyk, Tomasz, et al. "The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133314
Kowalczyk T, Kisluk J, Pietrowska K, Godzien J, Kozlowski M, Reszeć J, Sierko E, Naumnik W, Mróz R, Moniuszko M, Kretowski A, Niklinski J, Ciborowski M. The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied. Cancers (Basel). 2021 Jul 01;13(13). doi: 10.3390/cancers13133314. PMID: 34282765; PMCID: PMC8268630.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2021 Jul 01;13(13). doi: 10.3390/cancers13133314.

The Ability of Metabolomics to Discriminate Non-Small-Cell Lung Cancer Subtypes Depends on the Stage of the Disease and the Type of Material Studied.

Cancers

Tomasz Kowalczyk, Joanna Kisluk, Karolina Pietrowska, Joanna Godzien, Miroslaw Kozlowski, Joanna Reszeć, Ewa Sierko, Wojciech Naumnik, Robert Mróz, Marcin Moniuszko, Adam Kretowski, Jacek Niklinski, Michal Ciborowski

Affiliations

  1. Metabolomics Laboratory, Clinical Research Centre, Medical University of Bialystok, M. Sk?odowskiej-Curie 24a, 15-276 Bialystok, Poland.
  2. Department of Clinical Molecular Biology, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland.
  3. Department of Thoracic Surgery, Medical University of Bialystok, M. Sk?odowskiej-Curie 24a, 15-276 Bialystok, Poland.
  4. Department of Medical Patomorphology, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland.
  5. Department of Oncology, Medical University of Bialystok, Ogrodowa 12, 15-027 Bialystok, Poland.
  6. 1st Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, ?urawia 14, 15-540 Bialystok, Poland.
  7. 2nd Department of Lung Diseases and Tuberculosis, Medical University of Bialystok, ?urawia 14, 15-540 Bialystok, Poland.
  8. Department of Allergology and Internal Medicine, Medical University of Bialystok, M. Sk?odowskiej-Curie 24a, 15-276 Bialystok, Poland.
  9. Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Waszyngtona 13, 15-269 Bialystok, Poland.
  10. Department of Endocrinology, Diabetology and Internal Medicine, Medical University of Bialystok, M. Sk?odowskiej-Curie 24a, 15-276 Bialystok, Poland.

PMID: 34282765 PMCID: PMC8268630 DOI: 10.3390/cancers13133314

Abstract

Identification of the NSCLC subtype at an early stage is still quite sophisticated. Metabolomics analysis of tissue and plasma of NSCLC patients may indicate new, and yet unknown, metabolic pathways active in the NSCLC. Our research characterized the metabolomics profile of tissue and plasma of patients with early and advanced NSCLC stage. Samples were subjected to thorough metabolomics analyses using liquid chromatography-mass spectrometry (LC-MS) technique. Tissue and/or plasma samples from 137 NSCLC patients were analyzed. Based on the early stage tissue analysis, more than 200 metabolites differentiating adenocarcinoma (ADC) and squamous cell lung carcinoma (SCC) subtypes as well as normal tissue, were identified. Most of the identified metabolites were amino acids, fatty acids, carnitines, lysoglycerophospholipids, sphingomyelins, plasmalogens and glycerophospholipids. Moreover, metabolites related to N-acyl ethanolamine (NAE) biosynthesis, namely glycerophospho (N-acyl) ethanolamines (GP-NAE), which discriminated early-stage SCC from ADC, have also been identified. On the other hand, the analysis of plasma of chronic obstructive pulmonary disease (COPD) and NSCLC patients allowed exclusion of the metabolites related to the inflammatory state in lungs and the identification of compounds (lysoglycerophospholipids, glycerophospholipids and sphingomyelins) truly characteristic to cancer. Our results, among already known, showed novel, thus far not described, metabolites discriminating NSCLC subtypes, especially in the early stage of cancer. Moreover, the presented results also indicated the activity of new metabolic pathways in NSCLC. Further investigations on the role of NAE biosynthesis pathways in the early stage of NSCLC may reveal new prognostic and diagnostic targets.

Keywords: advanced stage; early stage; metabolomics; non-small-cell lung cancer

References

  1. Sci Rep. 2019 Jul 16;9(1):10319 - PubMed
  2. Onco Targets Ther. 2016 Jul 18;9:4323-36 - PubMed
  3. Br J Cancer. 2015 Nov 17;113(10):1493-501 - PubMed
  4. Nat Rev Cancer. 2014 Aug;14(8):535-46 - PubMed
  5. Ann Glob Health. 2019 Jan 22;85(1): - PubMed
  6. Toxins (Basel). 2016 Nov 08;8(11): - PubMed
  7. Lung Cancer. 2011 Nov;74(2):284-92 - PubMed
  8. Cancer Prev Res (Phila). 2016 Jan;9(1):43-52 - PubMed
  9. J Proteome Res. 2019 Feb 1;18(2):797-802 - PubMed
  10. PLoS One. 2012;7(2):e31982 - PubMed
  11. Carcinogenesis. 2017 Jan 3;38(3):271-280 - PubMed
  12. Cancers (Basel). 2019 Dec 21;12(1): - PubMed
  13. Mol Oncol. 2018 Oct;12(10):1778-1796 - PubMed
  14. J Biol Chem. 2006 Sep 8;281(36):26465-72 - PubMed
  15. Bioinformation. 2017 Jun 30;13(6):202-208 - PubMed
  16. Adv Med Sci. 2017 Sep;62(2):405-413 - PubMed
  17. J Cancer Res Clin Oncol. 2015 Apr;141(4):705-18 - PubMed
  18. Oncotarget. 2016 Mar 15;7(11):12904-16 - PubMed
  19. Biochem Biophys Res Commun. 2020 May 21;526(1):246-252 - PubMed
  20. BMC Cancer. 2010 Dec 22;10:690 - PubMed
  21. Br J Cancer. 2008 Feb 26;98(4):742-8 - PubMed
  22. Lipids Health Dis. 2018 Mar 7;17(1):41 - PubMed
  23. Exp Ther Med. 2019 Jul;18(1):188-198 - PubMed
  24. Cancers (Basel). 2020 Mar 07;12(3): - PubMed
  25. Oncotarget. 2017 Nov 11;8(64):107899-107906 - PubMed
  26. Signal Transduct Target Ther. 2019 Dec 17;4:61 - PubMed
  27. Lipids Health Dis. 2015 Jul 11;14:69 - PubMed
  28. Lipids Health Dis. 2017 May 3;16(1):87 - PubMed
  29. Int J Biol Markers. 2018 Aug;33(3):314-320 - PubMed
  30. Curr Top Dev Biol. 2015;114:241-65 - PubMed
  31. Metabolites. 2019 Jun 10;9(6): - PubMed
  32. Electrophoresis. 2017 Sep;38(18):2304-2312 - PubMed
  33. Cancer Prev Res (Phila). 2015 May;8(5):410-8 - PubMed
  34. Metabolomics. 2013 Apr;9(2):444-453 - PubMed
  35. Oncotarget. 2016 Jun 14;7(24):36622-36631 - PubMed
  36. Sci Rep. 2017 Sep 11;7(1):11087 - PubMed
  37. Inflamm Bowel Dis. 2019 Jun 18;25(7):1120-1128 - PubMed
  38. Anticancer Res. 2017 Nov;37(11):6015-6023 - PubMed
  39. Cancer Epidemiol Biomarkers Prev. 2015 Nov;24(11):1716-23 - PubMed
  40. Anal Chim Acta. 2018 Dec 11;1037:256-264 - PubMed
  41. Metabolomics. 2016;12:146 - PubMed
  42. BBA Clin. 2016 Apr 03;5:186-92 - PubMed
  43. Cancers (Basel). 2018 Jul 27;10(8): - PubMed
  44. Lipids. 2008 Jan;43(1):79-89 - PubMed
  45. PLoS One. 2017 Sep 14;12(9):e0185011 - PubMed
  46. Eur Respir J. 2017 Apr 5;49(4): - PubMed
  47. J Cancer. 2019 Oct 8;10(23):5874-5882 - PubMed
  48. Sci Rep. 2018 May 8;8(1):7137 - PubMed
  49. Nat Rev Cancer. 2018 Jan;18(1):33-50 - PubMed
  50. Lung Cancer. 2017 Oct;112:69-74 - PubMed
  51. Cancer Lett. 2018 Jan 1;412:194-207 - PubMed
  52. J Clin Oncol. 2015 Nov 20;33(33):3880-6 - PubMed
  53. Oncol Lett. 2018 Aug;16(2):1390-1396 - PubMed
  54. Mol Cancer. 2009 Jun 26;8:41 - PubMed
  55. J Proteome Res. 2015 Aug 7;14(8):3204-16 - PubMed
  56. Carcinogenesis. 2015 Jan;36(1):68-75 - PubMed
  57. Oncol Lett. 2018 Apr;15(4):5473-5480 - PubMed
  58. Angiogenesis. 2011 Sep;14(3):321-30 - PubMed

Publication Types

Grant support